bluuebunny/crossref_metadata_2025_split huggingface dataset:
P070 Rheum to Empower: Home Spirometry and Oximetry Monitoring in Connective Tissue Related Interstitial Lung Disease
Authors: Ng Wan Lin , Howard Donough , Durcan Laura , Hurley Killian 
Published: April 2024

Abstract

Background/Aims
Interstitial lung disease (ILD) is a common cause of morbidity and mortality in connective tissue diseases (CTDs). Distinct challenges arise for individuals with impairments from rheumatic diseases, especially when coupled with respiratory symptoms. While home spirometry monitoring is valuable for patients with idiopathic pulmonary fibrosis (IPF), its applicability in CTD related ILD (CTD-ILD) is relatively unexplored. This study examines the feasibility and acceptability of home spirometry and oximetry monitoring in CTD-ILD patients compared with those with IPF.

Methods
Patients with CTD-ILD and IPF were recruited prospectively in a tertiary hospital. A portable handheld spirometer (MIR Spirobank Smart) and a Nonin finger oximeter linked to a smartphone app were provided, and patients were educated on its use. Spirometry and oximetry results were collated. At six months, a survey was conducted to assess patients’ perception of home monitoring.

Results
Fourty-one patients with CTD-ILD and 51 with IPF were recruited. The median ages were 66 and 71 years respectively (Table 1). 2946 FVC and 2787 oximetry readings were captured in the CTD-ILD cohort compared with 4984 FVC and 4778 oximetry readings in the IPF cohort. Among the 41 patients, 12 experienced Raynaud’s phenomenon. Only 7.32% (3/41) of CTD-ILD patients required an ear oximeter due to inaccurate oxygen saturation measurement caused by Raynaud’s phenomenon. Among the CTD-ILD cohort, 16.67% (6/36) experienced difficulty using the devices due to hand problems, while none of the IPF cohort encountered such issues. In the survey, patients reported barriers to long-term remote monitoring usage included forgetting to use, coughing or breathlessness. Less than one-third of patients indicated that spirometry and oximetry results contributed to health anxiety. A majority of patients found home monitoring useful and insightful, and would recommend this to others.

Conclusion
Our findings suggest the practicality of remotely monitoring FVC and oximetry in CTD-ILD patients, even with challenges like Raynaud’s phenomenon and impaired hand function. This not only underscores feasibility but also empowers patients through continuous monitoring despite physical limitations. Incorporating remote monitoring into standard care should be regarded as an essential approach for this understudied population, enhancing both clinical management and patient empowerment.

Disclosure
W. Ng: Grants/research support; StAR MD Scholarship, ISR Rheumatology Patient Initiative Fund. D. Howard: None. L. Durcan: None. K. Hurley: Grants/research support; Health Research Board, Ireland, Emerging Clinical Scientist Award (ECSA-2020-011).
P076 Exploring the correlation between body mass index and fracture risk in men
Authors: Nguyen Mai H , Bukhari Marwan 
Published: April 2024

Abstract

Background/Aims
There has been an increase in interest in identifying patients with high risk of fracture, due to the high mortality. In De Laet et al. (2005) meta-analysis on 60000 women and men, which analysed the effect of body mass index (BMI), bone mineral density (BMD), age and gender on risk of any fracture; low BMI is linked to significantly higher fracture risk (two-fold at BMI of 20) when compared with a BMI 25. On the same comparison, high BMI (30) reduced risk of fractures by 17% (RR 0.83). This was significant in women, but not in men. No newer large-scale study focused on the correlation between BMI and fracture risks in men. Therefore, we set out to investigate the relationship between BMI and different fractures in male patients.

Methods
5388 male patients referred for DEXA scan in the North West of England between 2004 and 2019 were included in the analysis. Logistic regression is performed for age, BMI, and BMD using R-4.3.1 for Windows.

Results
Prior to adjusting for BMD, low BMI is a significant risk factor for femur fracture. On the other hand, low BMI is a protective factor against tibia-fibula fractures. There was no significant correlation detected in spine, rib, humerus, forearm and elbow fractures. After adjusting for BMD, higher BMI is associated with significantly higher odds of humerus, tibia-fibula and wrist fractures, but no statistically significant association with spine, ribs and femur fractures.

Conclusion
Our results show the correlation between BMI, adjusted for BMD, and different fracture site. Our findings corroborated with previous literature, suggesting that BMI is likely a risk factor that is dependent on BMD. Furthermore, we highlighted that higher BMI is a protective factor for some fractures whilst being a risk factor for others. It is unclear whether the difference between the fracture types are due to the mechanism of fracture or the difference in disease progression at the different fracture sites - this is a potential area for future research.

Disclosure
M.H. Nguyen: None. M. Bukhari: None.
P078 United Kingdom rates and determinants of romosozumab prescriptions, a need for greater action
Authors: Javaid Muhammad K , Jones Tim , Hepworth Stepehn 
Published: April 2024

Abstract

Background/Aims
Romosozumab rapidly reduces fracture risk and has been recommended as a first-line option for post-menopausal persons with severe osteoporosis and a recent major fracture from November 2020 (Scotland) and May 2022 (England, Northern Ireland and Wales). Aim: to describe hospital-level romosozumab prescriptions and the determinants across the four nations.

Methods
Hospital-level romosozumab prescription data were analysed by country. Potential predictors included surrogates of local patient need (the population of women aged 50 years and over), local FLS status (none, partial, full) and, in England and Wales, the number of patient records submitted to the mandatory national audits for Fracture Liaison Service (FLSDB) and National Hip Fracture Database (NHFD) in 2021. Spearman correlations and zero-inflated Poisson models identified independent determinants of: a) any prescription and b) the number of prescriptions or romosozumab.

Results
152 sites were included (England-126, N. Ireland-5, Scotland-14, and Wales-7) with 60 full and 28 partial FLSs. 63 sites recorded a least one romosozumab prescription in 2022. The proportion of hospitals with any prescription varied from 20% in Northern Ireland to 64.3% in Scotland. An estimated four million women aged 50+ lived in areas with no romosozumab delivery. No determinants of any prescription were identified. With England as the referent group, the number of prescriptions was greater in Scotland (p = 0.001) and lower in Northern Ireland (p = &lt;0.001). After adjusting for the number of women aged 50 years and over (p = 0.008), a full FLS but not partial FLS predicted the number of prescriptions (Figure). In England and Wales both local NHFD (Rs = 0.19, p = 0.03) and FLSDB records (Rs = 0.25, p = 0.056) predicted the number of local prescriptions.

Conclusion
Even after inclusion in national guidelines, there is a care gap of at least four million women in the UK. In NHS sites that have started prescribing romosozumab, the patient numbers are significantly below expected rates. A national implementation strategy should be considered for decision makers, healthcare providers and patient groups to minimise the number of subsequent fragility fractures in the FLS setting by increasing the number of sites implementing romosozumab focusing on FLS first and matching local delivery to local population needs.

Disclosure
M.K. Javaid: Consultancies; MKJ has received honoraria, travel and/or subsistence expenses from: Amgen, Kyowa Kirin Hakin, UCB, Abbvie, Besin Healthcare, Sanofi. Grants/research support; MKJ has received unrestricted research grants Amgen, Kyowa Kirin Hakin, UCB. T. Jones: Corporate appointments; Employee of British and Irish BioPharma SPRL. S. Hepworth: Corporate appointments; Employee UCB BioPharma SPRL.
P088 Uveitis screening in Juvenile Idiopathic Arthritis: Are we following the guidelines?
Authors: Ahmad Junaid , Gupta Aashish , Bharadwaj Anurag , Olusanya Deborah 
Published: April 2024

Abstract

Background/Aims
Juvenile Idiopathic Arthritis (JIA) is the most common inflammatory arthritis in children. Uveitis is a common (8-30%) and potentially sight-threatening complication of JIA. Early detection and treatment of uveitis can prevent permanent visual impairment, making uveitis screening an essential part of the management of JIA patients. The purpose of this audit was to evaluate the referral and management of uveitis screening in JIA patients in our healthcare setting compared with Guidelines for Screening for Uveitis in Juvenile Idiopathic Arthritis (JIA) produced jointly by BSPAR and the RCOphth 2006.

Methods
The patients with a diagnosis of JIA at our District General Hospital (DGH) were reviewed retrospectively. The data was collected based on demographics, JIA diagnosis, subtypes, referral for uveitis screening, timing of uveitis screening, and screening outcome. Data was then analysed to assess if we met BSPAR and the RCOphth 2006 standards.

Results
A total of 42 patients were identified with a diagnosis of JIA between January 2021 and January 2023. Based on our criteria, four patients were excluded and the final analysis was done with 38 patients. 34 patients (89%) with JIA were referred for uveitis screening. 31 of those patients (91%) were referred within six weeks, while three patients (9%) were referred after six weeks of diagnosis. Only nine patients (24%) were seen for uveitis screening within the six weeks after initial referral as per BSPAR and the RCOphth 2006 standards. Uveitis was diagnosed in five patients(13%). One out of 38(2.6%) patients was diagnosed with Uveitis prior to diagnosis of JIA. Regarding the distribution of JIA subtypes, there were 15 cases of Polyarticular JIA, 14 instances of Oligoarticular JIA, six occurrences of Psoriatic JIA, two instances of Enthesitis-related JIA, and 1 case of Systemic JIA. Out of the five patients diagnosed with Uveitis, two had Polyarticular JIA, two had Oligoarticular JIA, and one presented with Psoriatic JIA. Furthermore, two of these patients tested positive for ANA, one tested negative, while the ANA status remained unknown for the remaining two individuals.

Conclusion
The results showed the need for improvement to be fully compliant with the guidelines for screening uveitis in JIA patients. We aim to ensure that all patients are referred and reviewed within 6 weeks for uveitis screening, as early detection and treatment of uveitis can prevent permanent visual impairment. We recommend collaborating with the ophthalmology unit to streamline the referral pathway and explore the idea of doing MDT clinics. Education should be arranged to raise awareness among all relevant healthcare staff.

Disclosure
J. Ahmad: None. A. Gupta: None. A. Bharadwaj: None. D. Olusanya: None.
P089 Comprehensive comparison of current guidelines in the management of Systemic Lupus Erythematosus in children, with a focus on Lupus Nephritis
Authors: Day Josephine A , Beresford Michael W 
Published: April 2024

Abstract

Background/Aims
Lupus nephritis (LN) is a common complication of systemic lupus erythematosus (SLE); LN affects 50-60% of those with a diagnosis of childhood-SLE (cSLE). Currently one set of paediatric recommendations exists for the diagnosis and treatment of LN, published by the Single Hub and Access point for Paediatric Rheumatology in Europe (SHARE). This paper compares SHARE recommendations against two current sets of adult guidelines, published by the British Society of Rheumatology (BSR) and the European Alliance of associations for Rheumatology (EULAR). This paper aims to identify similarities and differences between the three sets of guidelines, and to evaluate the evidence base used to formulate them.

Methods
Paediatric SHARE recommendations were recorded within a spreadsheet. The recommendations were separated into recommendations for diagnosis and recommendations for treatment. The BSR paper was then examined for equivalent guidelines. The evidence level was recorded for each guideline. In the second phase, the EULAR 2019 guidelines were assessed for corresponding guidelines to the SHARE recommendations. EULAR levels of evidence were recorded. A Likert score of similarity (0-10) was assigned to each trio of guidelines (the trio consisting of one each from SHARE, BSR and EULAR). If a comparable guideline couldn’t be found in either the BSR or EULAR papers, this is made clear in the table.

Results
When comparing six diagnostic SHARE recommendations for paediatric LN with equivalent BSR and EULAR guidelines, the Likert similarity score ranged between 0-9. Only 50% of the 20 treatment SHARE recommendations had a Likert score ≥5 with their equivalent BSR and EULAR guidelines. Three SHARE treatment recommendations had no comparable guidelines, these are clearly identified in the results tables. All SHARE recommendations were based on level 3 or 4 evidence. Level 3 evidence comes from descriptive studies, whilst level 4 evidence comes from expert opinion and is considered the lowest level of evidence.

Conclusion
The quantity of differences noted in this paper leads to questioning whether transitional guidelines should be developed for care of young adults with LN to ensure safe transition as they move from paediatric to adult medical care. LN is a chronic condition that will impact a child’s entire life. Optimising care from as early in life as possible and continuing this into the future is essential to maximising quality of life and reducing adverse outcomes associated with renal involvement.

Disclosure
J.A. Day: None. M.W. Beresford: None.
P091 Is my arthritis part of who I am or something I have? Age of onset makes a difference
Authors: Beesley Richard P , Beesley Rebecca M , Middleton Kate , McBride Andrea 
Published: April 2024

Abstract

Background/Aims
Patients with rheumatic and musculoskeletal conditions experience a wide range of emotions, and reflect differently upon their diagnosis.
This collaborative study between three patient organisations explored how a diagnosis of a rheumatic condition affected a patient’s identity with the disease.

Methods
Adults in the UK aged 18+ who had any diagnosis of a musculoskeletal or rheumatic condition were invited to complete an online survey. Respondents provided information about their diagnosis, experiences and attitudes across a range of themes and topics. Respondents were asked to indicate how they felt about their condition, scoring between whether they felt their condition was “part of who I am” (score 0) or “something I have” (score 10).

Results
In total, 532 respondents completed the survey (64% female; 68% White ethnicity). The mean overall score was 6.28 (tending towards “something I have”). There was no difference between male and female respondents, nor between ethnic groups. However, there was a significant difference between patients with a diagnosis of Juvenile Arthritis (JA, including juvenile idiopathic arthritis, juvenile chronic arthritis, and juvenile rheumatoid arthritis) compared to other respondents, with JA patients more likely to consider their arthritis “part of who I am” (5.25 compared to 6.75; p&lt;.05). By age band, older patients (aged 56+) were more likely to consider their arthritis “something I have” compared to younger patients (aged under 25, 26-35 or 36-45 p&lt;.05), with a trend of increasing score based both on age and age at diagnosis.

Conclusion
A diagnosis of a rheumatic or musculoskeletal disease (RMD) has a substantial impact on patients, and can affect their sense of identity. Patients with earlier onset are more likely to consider their arthritis to be a part of who they are, rather than a condition they have. This may impact on motivations and expectations. Further research into this may help identify how to better support patients in relation to how they perceive their condition.

Disclosure
R.P. Beesley: None. R.M. Beesley: None. K. Middleton: None. A. McBride: None.
P109 Ocular manifestation of rheumatoid arthritis
Authors: Fenniche Insaf , Aydi Zohra , Somai Mehdi , Daoud Fatma , Dhaou Besma Ben , Kochbati Samir , Rachdi Imene , Boussema Fatma 
Published: April 2024

Abstract

Background/Aims
Ocular manifestation associated with rheumatoid arthritis (RA) is common and should be systematically investigated by an ophthalmological examination. It may precede or complicate the disease. It manifests as a dry-eye syndrome in 38% to 45% of cases, scleritis in 0.2 to 6.3% of cases, episcleritis in 0.17 to 3.7% of cases, and peripheral ulcerative keratitis in 3% of cases. The aim of this study was to describe ocular involvement in RA and to identify factors predictive of its occurrence.

Methods
This is a retrospective study of patients with RA defined according to the ACR- EULAR 2010 criteria, followed up in the internal medicine department between 2015 and 2022. Patients were divided into two groups: G0 including patients without ocular involvement and G1 including patients with ocular involvement.

Results
Eighty patients were diagnosed, 65 women and 15 men, giving a sex ratio (F/H) of 4.33. The mean age was 60.79 years [extremes: 30-90 years]. The mean age of disease onset was 46.34 years [extremes: 22-82 years]. Among our 80 patients, 20 had RA-related ocular involvement (25%). These included 18 women and two men. Ocular involvement consisted of dry-eye syndrome (17 cases), superficial punctate keratitis (4 cases), corneal perforation (one case), and unilateral diffuse scleritis (one case). The ocular examination had also revealed corticosteroid adverse effects: corticosteroid-induced cataract (four cases) and corticosteroid-induced glaucoma (three cases). Sjogren’s syndrome associated with RA was present in 76.47% of cases. There was no difference between the two groups in terms of age (62.25 vs. 44.22 years, p = 0.943), age of disease onset (47, 23 years vs. 44.22 years, p = 0.569), rheumatoid factor level (335.29 IU/L vs. 329.15 IU/L, p = 0.393) and anti-CCP antibody level (225.08 IU/L vs. 119.23 IU/L, p = 0.070). CRP was significantly higher in patients with no ocular involvement (225.08 mg/l vs. 118.23 mg/l, p = 0.007). erosive character was observed more in G0 than in G1, but without any significant difference, respectively 85.29% vs. 68.42%; p = 0.146.

Conclusion
According to our study, a quarter of patients followed for RA had ocular manifestations dominated mainly by dry syndrome. However, no predictive risk factor was found for this condition, be it clinical, immunological, or radiological.

Disclosure
I. Fenniche: None. Z. Aydi: None. M. Somai: None. F. Daoud: None. B. Ben dhaou: None. S. Kochbati: None. I. Rachdi: None. F. Boussema: None.
P120 Characteristics of difficult-to-treat rheumatoid arthritis: results from a systematic literature review
Authors: Chambers Sachin , Croft Adam P , Singh Ruchir 
Published: April 2024

Abstract

Background/Aims
Estimates predict between 10-20% of RA patients meet difficult-to-treat Rheumatoid Arthritis (D2T-RA) classification, representing a clinically distinct cohort. There is a significant unmet need in the identification and management of these patients. Discerning significant characteristics across cohorts may identify predictors for D2T-RA, which may prompt earlier clinical recognition and patient-tailored, holistic management to improve clinical outcomes. This review aims to describe the clinical characteristics of patients with EULAR-defined D2T-RA to help identify and manage predictors, contributory factors, or consequences of difficult-to-treat disease.

Methods
A systematic literature search of PubMed, Embase and Web of Science databases for studies pertaining to characteristics of D2T-RA was undertaken from database inception to May 2023. Results were screened against strict inclusion/exclusion criteria. Risk-of-bias (RoB) assessments were performed using the Newcastle-Ottawa Scale (NOS) and a modified version for cross-sectional studies (mNOS). Significant (p &lt; 0.05) baseline characteristics between D2T-RA and non-D2T patients were extracted for comparison following thematic analysis. Where there was conflict in the direction of the extracted characteristics; the number and quality of studies were used to resolve evidential disagreements.

Results
1687 studies were identified, of which seven fulfilled the inclusion criteria. Included studies were observational, published between 2021 and 2023, with mean D2T and non-D2T sample sizes of 83 and 417 patients, respectively. Five of the seven cohorts were European, with two from Japan. Following RoB and dispute resolution, all seven identified studies were included for analysis. Key themes elucidated are shown in table 1. Of note, significant characteristics included female sex, autoantibody positivity, greater annual bone erosion progression, interstitial lung disease, mental health conditions, and non-adherence.

Conclusion
Greater awareness of clinical characteristics of D2T-RA patients will assist clinicians by promoting the assessment of traits associated with poor treatment response. This is the first review to systematically describe characteristics of D2T-RA patients across multiple cohorts. Several commonly recorded, modifiable characteristics were associated with D2T-RA. Evidential disagreements and heterogeneous study designs were analytical barriers, and clinical intervention studies are needed to determine if addressing these factors in the routine clinical setting improves clinical outcomes and prevention in D2T-RA.

Disclosure
S. Chambers: None. A.P. Croft: None. R. Singh: None.